Study Information
| Study Detail | Information |
| ClinicalTrials.gov ID | NCT04697628 |
| Study Name | innovaTV 301 |
| Study Phase | Phase 3 |
| Participants | 502 adults |
| Condition Studied | Recurrent or metastatic cervical cancer |
| Investigational Treatment | Tisotumab vedotin |
| Compared With | Investigator’s choice of chemotherapy |
| Study Design | Randomized, open-label clinical trial |
| Reading Time | About 6 minutes |
Why Was This Study Done?
Many people with cervical cancer respond well to their first treatment. However, for some people, the cancer comes back after treatment (recurrent cancer) or spreads to other parts of the body (metastatic cancer). When this happens, treatment becomes much more difficult, and doctors have fewer options to control the disease.
Standard chemotherapy is often used after the cancer has returned or spread, but the results are not always encouraging. Many patients continue to see their cancer grow, and survival remains limited. Because of this, researchers have been looking for treatments that can help people live longer and keep their cancer under control for longer.
One of these newer treatments is tisotumab vedotin. It belongs to a group of medicines called antibody-drug conjugates (ADCs). These treatments combine two parts into one medicine:
- An antibody, which helps the treatment find cancer cells.
- A chemotherapy drug, which is released after the medicine enters the cancer cell.
Tisotumab vedotin targets a protein called tissue factor, which is found at high levels on many cervical cancer cells. Once the medicine attaches to the cancer cell, it enters the cell and releases its chemotherapy drug, called monomethyl auristatin E (MMAE), to help kill the cancer cell.
The innovaTV 301 study was designed to answer one important question:
Can tisotumab vedotin help people with recurrent or metastatic cervical cancer live longer than standard chemotherapy after one or two previous treatments have stopped working?
What Did the Study Find?
The innovaTV 301 study included 502 adults with recurrent or metastatic cervical cancer from many countries. Everyone in the study had already received one or two previous drug treatments for their recurrent or metastatic cancer.
Participants were randomly assigned to one of two treatment groups.
- One group received tisotumab vedotin every three weeks.
- The other group received one standard chemotherapy medicine chosen by their doctor. The chemotherapy options were topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed.
Because this was an open-label study, both the patients and their doctors knew which treatment each person received.
Researchers wanted to compare the two groups in several important ways:
- How long people lived after joining the study (overall survival)
- How long the treatment kept the cancer under control before it started growing again (progression-free survival)
- How many people’s tumors became smaller during treatment (objective response rate)
- How safe each treatment was
People receiving tisotumab vedotin lived longer
The study reached its main goal.
People who received tisotumab vedotin lived a median of 11.5 months, compared with 9.5 months for people who received chemotherapy.
In simple terms, people treated with tisotumab vedotin lived about two months longer, on average, than those treated with standard chemotherapy.
Researchers also estimated that people receiving tisotumab vedotin were about 30% less likely to die during the study than those receiving chemotherapy. This difference was unlikely to be due to chance, giving researchers confidence that the treatment provided a real benefit.
The treatment kept the cancer under control for longer
Researchers also looked at how long the treatment could keep the cancer from getting worse.
On average, the cancer stayed under control for 4.2 months in people receiving tisotumab vedotin, compared with 2.9 months in those receiving chemotherapy.
Although this may seem like a small difference, delaying cancer growth can give patients more time before needing another treatment and may help maintain their quality of life.
More people’s tumors became smaller
Another important question was whether the treatment could shrink tumors.
The study found that tumors became smaller in about 18 out of every 100 people treated with tisotumab vedotin, compared with about 5 out of every 100 people who received chemotherapy.
Some people had complete responses, meaning doctors could no longer detect signs of cancer on their scans. Others had partial responses, meaning their tumors became noticeably smaller.
Overall, tisotumab vedotin was much more likely to shrink tumors than standard chemotherapy in this study.
Safety Findings
Like most cancer treatments, tisotumab vedotin caused side effects. Almost everyone in both treatment groups experienced at least one side effect during the study. However, most side effects were expected and could usually be managed with careful monitoring and supportive care.
One of the most important side effects seen with tisotumab vedotin involved the eyes. Some people developed problems such as:
- Dry eyes
- Red or irritated eyes (conjunctivitis)
- Changes to the surface of the eye
To help reduce these problems, everyone receiving tisotumab vedotin followed a special eye-care plan during treatment. This included regular eye examinations and preventive eye drops before and after each treatment.
Other common side effects included:
- Feeling tired (fatigue)
- Feeling sick (nausea)
- Nosebleeds
- Numbness or tingling in the hands or feet (peripheral neuropathy)
Researchers also looked at serious side effects, sometimes called Grade 3 or higher adverse events. These are side effects that usually need medical treatment or may require patients to stop or delay treatment.
Serious side effects occurred in:
- 52 out of every 100 people receiving tisotumab vedotin
- 62 out of every 100 people receiving chemotherapy
In addition, about 15 out of every 100 people receiving tisotumab vedotin stopped treatment because of side effects.
Overall, the study found that the side effects of tisotumab vedotin were different from those of chemotherapy but were generally manageable when patients were monitored carefully.
What Do These Results Mean?
The innovaTV 301 study showed that tisotumab vedotin worked better than standard chemotherapy for adults with recurrent or metastatic cervical cancer whose disease had continued to grow after one or two previous drug treatments.
Compared with chemotherapy, people receiving tisotumab vedotin:
- Lived longer (11.5 months compared with 9.5 months)
- Were about 30% less likely to die during the study
- Kept their cancer under control for longer (4.2 months compared with 2.9 months)
- Were more likely to have their tumors shrink (about 18 out of every 100 people compared with about 5 out of every 100)
- Had fewer serious side effects overall (52 out of every 100 people compared with 62 out of every 100)
For people whose cervical cancer has returned or spread after earlier treatment, these improvements are important because there are relatively few treatment options available. Even though the average improvement in survival was about two months, delaying the cancer from getting worse and increasing the chance of tumor shrinkage may provide meaningful benefits for some patients.
What are the strengths of this study?
Several features make the results more reliable.
First, innovaTV 301 was a Phase 3 clinical trial. Phase 3 studies are large studies designed to compare a new treatment with the current standard treatment before decisions about wider use are made.
Second, the study included 502 participants from many countries. This makes it more likely that the findings apply to a broad range of patients who are similar to those enrolled in the trial.
Finally, the study compared tisotumab vedotin directly with standard chemotherapy rather than with a placebo (a treatment with no active medicine). This provides a practical comparison for doctors and patients.
What are the limitations?
Like every clinical trial, this study has some limitations.
The results apply only to adults with recurrent or metastatic cervical cancer whose disease had progressed after one or two previous systemic treatments. They do not tell us whether the treatment works as a first treatment for cervical cancer or for people with earlier-stage disease.
The study was also open-label, meaning patients and doctors knew which treatment was being given. While this is unlikely to affect results such as overall survival, it could influence how some side effects were reported.
Another point to remember is that the study compared tisotumab vedotin with single-agent chemotherapy, which was an accepted standard treatment during the trial. As cervical cancer treatment continues to change, future studies may compare tisotumab vedotin with newer treatment combinations or explore its use in different stages of the disease.
Trialora’s Bottom Line
The innovaTV 301 study found that tisotumab vedotin helped people with recurrent or metastatic cervical cancer live longer than standard chemotherapy after previous treatments had stopped working.
People who received the treatment were also more likely to have their tumors shrink and spent longer before their cancer started growing again. Although side effects were common, the study found fewer serious side effects overall with tisotumab vedotin than with standard chemotherapy.
These findings suggest that tisotumab vedotin is an effective treatment option for patients similar to those who took part in this study. However, every person’s situation is different, and treatment decisions should always be made together with a cancer specialist who can explain the benefits and risks for each individual.
References
- ClinicalTrials.gov. Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301). ClinicalTrials.gov Identifier: NCT04697628. Study Details and Results.
- Vergote I, González-Martín A, Fujiwara K, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. New England Journal of Medicine. 2024;391:44–55.
Medical Disclaimer
This article is for educational purposes only. It explains the results of a published clinical trial using information from ClinicalTrials.gov and a peer-reviewed scientific publication.
It is not medical advice and should not replace discussions with your doctor or cancer care team. The results described in this article apply only to the people who took part in the innovaTV 301 study and may not apply to everyone with cervical cancer.
Trialora independently explains publicly available clinical trial results in plain language using information from ClinicalTrials.gov and peer-reviewed scientific publications, where available. Trialora is not affiliated with the study sponsor or any regulatory authority.
